share_log

Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know

カリディタスセラピューティクスのアナリスト評価から得られる重要な洞察:知っておく必要があること

Benzinga ·  05/31 16:01

In the last three months, 5 analysts have published ratings on Calliditas Therapeutics (NASDAQ:CALT), offering a diverse range of perspectives from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings10400
Last 30D00100
1M Ago10300
2M Ago00000
3M Ago00000

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.4, along with a high estimate of $45.00 and a low estimate of $39.00. Highlighting a 25.64% decrease, the current average has fallen from the previous average price target of $54.33.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

A clear picture of...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする